Summary
McKesson Corporation reported its financial results for the second quarter and first half of fiscal year 2025. Total revenues saw a significant increase of 21% for the quarter and 14% for the six-month period, driven by growth in the U.S. Pharmaceutical segment and increased pharmaceutical distribution volumes internationally. However, diluted earnings per share decreased substantially, reflecting higher operating expenses and specific charges. Key items impacting the results include a substantial charge of $643 million related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell. Additionally, the company incurred $227 million in restructuring charges for enterprise-wide technology modernization initiatives. The company also continues to manage its significant estimated liability for opioid-related claims, totaling $6.4 billion as of period end. Despite the earnings decline, McKesson demonstrated strong operational cash flow and continued to return capital to shareholders through share repurchases ($2.0 billion in the first half) and a raised quarterly dividend. The company also announced a significant acquisition in the oncology sector, pending regulatory approval.
Financial Highlights
52 data points| Revenue | $93.65B |
| Cost of Revenue | $90.40B |
| Gross Profit | $3.25B |
| SG&A Expenses | $2.50B |
| Operating Expenses | $2.67B |
| Operating Income | $578.00M |
| Interest Expense | $78.00M |
| Net Income | $241.00M |
| EPS (Basic) | $1.88 |
| EPS (Diluted) | $1.87 |
| Shares Outstanding (Basic) | 128.70M |
| Shares Outstanding (Diluted) | 129.30M |
Key Highlights
- 1Revenue increased by 21% year-over-year to $93.7 billion for the quarter and 14% to $172.9 billion for the six months, primarily driven by the U.S. Pharmaceutical segment and international operations.
- 2Diluted earnings per share declined significantly to $1.87 for the quarter (down from $4.92) and $8.89 for the six months (down from $11.95), reflecting higher operating expenses and specific charges.
- 3The company recorded a $643 million charge related to the remeasurement of its Canadian retail disposal group to fair value less costs to sell.
- 4Restructuring charges of $227 million were recognized for enterprise-wide initiatives to modernize technology and improve operating efficiency.
- 5McKesson announced a definitive agreement to acquire a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion.
- 6The company returned $2.2 billion to shareholders through $2.0 billion in stock repurchases and $162 million in dividends during the first half of the fiscal year.
- 7The total estimated liability for opioid-related claims stands at $6.4 billion as of September 30, 2024.